News | Amgen
Amgen Foundation Awards and Accolades How We Operate
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
May 16, 2024 · Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology
Newsroom - Amgen
Amgen is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Latest Press Releases
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
Oct 6, 2023 · Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
Amgen | A Worldwide Pioneer in Biotechnology
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF …
May 19, 2024 · Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external ...
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH …
Jun 1, 2023 · Amgen is currently investigating tarlatamab in multiple trials, including DeLLphi-301, a potentially registrational Phase 2 study in heavily pretreated SCLC. The DeLLphi-304 trial is a Phase 3 study comparing tarlatamab with standard of care chemotherapy in second-line treatment of SCLC. About Amgen Oncology
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND | Amgen Inc.
THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025. About Amgen
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION …
Dec 5, 2024 · Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
May 15, 2024 · Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external ...